Ann Surg Treat Res.  2024 May;106(5):274-283. 10.4174/astr.2024.106.5.274.

Epigenetic modulation inhibits epithelial-mesenchymal transition-driven fibrogenesis and enhances characteristics of chemically-derived hepatic progenitors

• Adisasmita M
• Lee HK
• An Y
• Kim M
• Mamo MG
• Hur JK
• Choi D
• Shin JH
• Jung YK

• KMID: 2555724
• DOI: http://doi.org/10.4174/astr.2024.106.5.274

Abstract

Purpose
One of the novel cell sources of cell-based liver regenerative medicine is human chemically-derived hepatic progenitors (hCdHs). We previously established this cell by direct hepatocyte reprogramming with a combination of small molecules (hepatocyte growth factor, A83-01, CHIR99021). However, there have been several issues concerning the cell’s stability and maintenance, namely the occurrences of epithelial-mesenchymal transition (EMT) that develop fibrotic phenotypes, resulting in the loss of hepatic progenitor characteristics. These hepatic progenitor attributes are thought to be regulated by SOX9, a transcription factor essential for hepatic progenitor cells and cholangiocytes.
Methods
To suppress the fibrotic phenotype and improve our long-term hCdHs culture technology, we utilized the epigenetic modulating drugs DNA methyltransferase inhibitor (5-azacytidine) and histone deacetylase inhibitor (sodium butyrate) that have been reported to suppress and revert hepatic fibrosis. To confirm the essential role of SOX9 to our cell, we used clustered regularly interspaced short palindromic repeats-interference (CRISPRi) to repress the SOX9 expression.
Results
The treatment of only 5-azacytidine significantly reduces the fibrosis/mesenchymal marker and EMT-related transcription factor expression level in the early passages. Interestingly, this treatment also increased the hepatic progenitor markers expression, even during the reprogramming phase. Then, we confirmed the essential role of SOX9 by repressing the SOX9 expression with CRISPRi which resulted in the downregulation of several essential hepatic progenitor cell markers.
Conclusion
These results highlight the capacity of 5-azacytidine to inhibit EMT-driven hepatic fibrosis and the significance of SOX9 on hepatic progenitor cell stemness properties.

Keyword

CRISPR; Epigenomics; Fibrosis; Hepatocytes; Human chemically-derived hepatic progenitors

Figure

• 

  Fig. 1 Effect of epigenetic modulating drugs (epidrugs) on the cellular reprogramming of human primary hepatocytes (hPHs) generation into human chemically-derived hepatic progenitors (hCdHs). (A) Scheme of the generation of hCdHs perfused hPHs with the treatment of epidrugs 5-azacytidine (5-Aza) and sodium butyrate (NaB). (B) Brightfield imaging of the reprogramming process of hCdHs with epidrugs treatment with different drug concentrations (5-Aza, 0.5 µM; NaB, 0–100 µM). Scale bars, 100 µm. (C–E) Relative messenger RNA (mRNA) expression level of hepatic progenitor markers (EpCAM, SOX9) (C), epithelial-mesenchymal transition-related transcription factor (TWIST1, SNAI1) (D), and mesenchymal marker (COL1A1) (E). Values are presented as mean ± standard error of mean in triplicates (n = 3). HAC, HGF, A83-01, CHIR-99021; HGF, hepatocyte growth factor; EpCAM, epithelial cell adhesion molecule; SOX9, SRY-box transcription factor 9; SNAI1, Snail family transcriptional repressor 1; TWIST1, twist family bHLH transcription factor 1; COL1A1, collagen type I alpha 1 chain; NS, not significant. *P < 0.05 and ****P < 0.001, by 2-tailed t-test.

• 

  Fig. 2 Epigenetic modulating drugs (epidrugs) inhibit epithelial-mesenchymal transition (EMT)-driven fibrogenesis by regulating the EMT transcription factors SNAI1 and TWIST1. (A) Brightfield imaging of human chemically-derived hepatic progenitors (hCdHs) and fibrotic hCdHs. (B) Schematic image of the treatment of 5-azacytidine (5-Aza) and sodium butyrate (NaB) on the long-term maintenance and culture of hCdHs. (C) Brightfield imaging of the long-term culture and expansion of hCdHs treated with epidrugs with different drug concentrations on day 2 and day 5 after passaging. Scale bars, 100 µm. (D–F) Relative messenger RNA (mRNA) expression level of hepatic progenitor markers (EpCAM, SOX9) (D), EMT-related transcription factor (TWIST1, SNAI1) (E), and mesenchymal marker (COL1A1) (F). Values are presented as mean ± standard error of mean in triplicates (n = 3). HAC, HGF, A83-01, CHIR-99021; HGF, hepatocyte growth factor; EpCAM, epithelial cell adhesion molecule; SOX9, SRY-box transcription factor 9; SNAI1, Snail family transcriptional repressor 1; TWIST1, twist family bHLH transcription factor 1; COL1A1, collagen type I alpha 1 chain; NS, not significant. *P < 0.05 and ****P < 0.001, by 2-tailed t-test.

• 

  Fig. 3 Clustered regularly interspaced short palindromic repeats-interference (CRISPRi)-mediated SOX9 knockdown demonstrates SOX9 essential role as a transcription factor of mouse chemically-derived hepatic progenitors (mCdHs). (A) Illustration of the SOX9 repression by CRISPRi electroporation. (B) SOX9 genome map shows the single guide RNA (sgRNA) target site (sgRNA#1, #4, and #5) relative to its transcription start site. (C) Brightfield imaging of the impact of SOX9 repression by CRISPRi with and without sgRNA transfection on mCdHs. Scale bars, 100 µm (a) and 500 µm (b). Relative messenger RNA (mRNA) expression level of hepatic progenitor markers (SOX9, AFP, KRT7, EpCAM, CD44) (D) and hepatic marker (ALB, HNF4A) (E). Values are presented as means ± standard error of mean in triplicates (n = 3). AFP, alpha-fetoprotein; KRT7, keratin 7; EpCAM, epithelial cell adhesion molecule; CD44, cluster of differentiation 44; ALB, albumin; HNF4A, hepatocyte nuclear factor 4 alpha. *P < 0.05 and ****P < 0.001, by 2-tailed t-test.

Reference

1. Oh SH, Swiderska-Syn M, Jewell ML, Premont RT, Diehl AM. Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes. J Hepatol. 2018; 69:359–367. PMID: 29758331.

2. Kim Y, Kang K, Lee SB, Seo D, Yoon S, Kim SJ, et al. Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells. J Hepatol. 2019; 70:97–107. PMID: 30240598.

3. Thorgersen EB, Barratt-Due A, Haugaa H, Harboe M, Pischke SE, Nilsson PH, et al. The role of complement in liver injury, regeneration, and transplantation. Hepatology. 2019; 70:725–736. PMID: 30653682.

4. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem. 2007; 282:22089–22101. PMID: 17513865.

5. Lu K, Liu G, Yang L, Liu F, Gao L, Shi J, et al. Sustainable inflammation transforms hepatic cells by causing oxidative stress injury and potential epithelial-mesenchymal transition. Int J Oncol. 2016; 49:971–980. PMID: 27315196.

6. Xue ZF, Wu XM, Liu M. Hepatic regeneration and the epithelial to mesenchymal transition. World J Gastroenterol. 2013; 19:1380–1386. PMID: 23538893.

7. Chen Z, Li S, Subramaniam S, Shyy JY, Chien S. Epigenetic regulation: a new frontier for biomedical engineers. Annu Rev Biomed Eng. 2017; 19:195–219. PMID: 28301736.

8. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010; 28:1069–1078. PMID: 20944599.

9. Paluch BE, Naqash AR, Brumberger Z, Nemeth MJ, Griffiths EA. Epigenetics: a primer for clinicians. Blood Rev. 2016; 30:285–295. PMID: 26969414.

10. Bedi U, Mishra VK, Wasilewski D, Scheel C, Johnsen SA. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget. 2014; 5:2016–2029. PMID: 24840099.

11. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008; 14:818–829. PMID: 18539112.

12. Lee CW, Chen YF, Wu HH, Lee OK. Historical perspectives and advances in mesenchymal stem cell research for the treatment of liver diseases. Gastroenterology. 2018; 154:46–56. PMID: 29107021.

13. Dhawan A, Chaijitraruch N, Fitzpatrick E, Bansal S, Filippi C, Lehec SC, et al. Alginate microencapsulated human hepatocytes for the treatment of acute liver failure in children. J Hepatol. 2020; 72:877–884. PMID: 31843649.

14. Ho CM, Chen YH, Chien CS, Ho SL, Chen HL, Hu RH, et al. Hepatocyte and mesenchymal stem cell co-transplantation in rats with acute liver failure. Korean J Transplant. 2020; 34:100–108. PMID: 35769351.

15. Mu N, Liu HB, Meng QH, Du DW, Jiang Y, Hu HZ. The differentiation of human multipotent adult progenitor cells into hepatocyte-like cells induced by coculture with human hepatocyte line L02. Ann Surg Treat Res. 2015; 88:1–7. PMID: 25553318.

16. Buisson EM, Park SH, Kim M, Kang K, Yoon S, Lee JE, et al. Transplantation of patient-specific bile duct bioengineered with chemically reprogrammed and microtopographically differentiated cells. Bioeng Transl Med. 2021; 7:e10252. PMID: 35079629.

17. Kim Y, Hong SA, Yu J, Eom J, Jang K, Yoon S, et al. Adenine base editing and prime editing of chemically derived hepatic progenitors rescue genetic liver disease. Cell Stem Cell. 2021; 28:1614–1624. PMID: 33951479.

18. Salas-Silva S, Kim Y, Kim TH, Kim M, Seo D, Choi J, et al. Human chemically-derived hepatic progenitors (hCdHs) as a source of liver organoid generation: application in regenerative medicine, disease modeling, and toxicology testing. Biomaterials. 2023; 303:122360. PMID: 38465578.

19. Nie YZ, Zheng YW, Taniguchi H. Improving the repopulation capacity of elderly human hepatocytes by decoding aging-associated hepatocyte plasticity. Hepatology. 2022; 76:1030–1045. PMID: 35243665.

20. Zhang W, Qu J, Liu GH, Belmonte JC. The ageing epigenome and its rejuvenation. Nat Rev Mol Cell Biol. 2020; 21:137–150. PMID: 32020082.

21. Tanimizu N, Ichinohe N, Yamamoto M, Akiyama H, Nishikawa Y, Mitaka T. Progressive induction of hepatocyte progenitor cells in chronically injured liver. Sci Rep. 2017; 7:39990. PMID: 28051157.

22. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology. 2009; 136:2325–2333. PMID: 19403103.

23. Kim M, Kim Y, Silva ES, Adisasmita M, Kim KS, Jung YK, et al. Enhancing generation efficiency of liver organoids in a collagen scaffold using human chemically derived hepatic progenitors. Ann Hepatobiliary Pancreat Surg. 2023; 27:342–349. PMID: 37661098.

24. Falahi F, Sgro A, Blancafort P. Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Front Oncol. 2015; 5:22. PMID: 25705610.

25. Mann DA. Epigenetics in liver disease. Hepatology. 2014; 60:1418–1425. PMID: 24633972.

26. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004; 23:2919–2933. PMID: 15077154.

27. Liu C, Liu L, Chen X, Cheng J, Zhang H, Shen J, et al. Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. Hepatology. 2016; 64:117–129. PMID: 26910875.

28. Pastore N, Huynh T, Herz NJ, Calcagni’ A, Klisch TJ, Brunetti L, et al. TFEB regulates murine liver cell fate during development and regeneration. Nat Commun. 2020; 11:2461. PMID: 32424153.